Publications du service

Principales publications scientifiques du service d'oncologie médicale de l'hôpital Saint Antoine de ces dix dernières années.

  • André T et al. on behalf MOSAIC Investigators . Adjuvant FOLFOX4 in stage II/III colon cancer - updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. Journal of Clin Oncol 2015 (online).
  • Tournigand C et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer: Results of the GERCOR DREAM randomised phase 3 study (OPTIMOX3). Lancet Oncol . 2015 Oct 13. pii: S1470-2045(15)00216-8. doi: 10.1016/S1470-2045(15)00216-8. [Epub ahead of print]
  • Borg C et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study . Ann Oncol 2014;25:2205-10.
  • Peeters M et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:107-16.
  • André Tet al.; for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status . Curr Colorectal Cancer Rep. 2013;9:261-269.
  • Bennouna J et al.; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
  • Shi Q et al. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database . J Clin Oncol. 2013;31(29):3656-63.
  • Kubicka S et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol. 2013 (9):2342-9.
  • Chibaudel B et al. Platinum-sensitivity in metastatic colorectal cancer: towards a definition . Eur J Cancer. 2013 49(18):3813-20.
  • André T et al.; GERCOR. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013;24:412-9.
  • Tournigand C et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353-60.
  • de Gramont A et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225-33.
  • Sargent DJ et al.; ARCAD Clinical Trials Program. The ARCAD clinical trials program: an update and invitation . Oncologist. 2012;17:188-91.
  • Tournigand C, de Gramont A. Chemotherapy: Is adjuvant chemotherapy an option for stage II colon cancer? Nat Rev Clin Oncol. 2011;8:574-6.
  • Buyse M et al.. The ARCAD advanced colorectal cancer database--open for business; ARCAD Clinical Trials Program . Ann Oncol. 2012;23:281-2.
  • Sargent D et al. Adjuvant Colon Cancer End-points (ACCENT) Group. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer. 2011;47(7):990-6.
  • Chibaudel B et al. Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy-An Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol. 2011;29:4199-204.
  • Chibaudel B et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study . Oncologist 2011;16:1228-38.
  • de Gramont A et al. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program . J Clin Oncol. 2010;28:527-30.
  • Buyse M et al. Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol. 2010 (6):309-17.
  • de Gramont A et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol, 2010, 28, 460-5.
  • Chibaudel B et al. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol 2009;20:1383-6.
  • Chibaudel B et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer ? The GERCOR OPTIMOX2 study . J Clin Oncol, 2009, 27, 5727-33.
  • André T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant tr.eatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 2009, 27, 3109-16.
  • Sargent D et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-7.
  • de Gramont A et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007;25:3224-9.
  • André T et al; GERCOR. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 2007;18:77-81.
  • Goldberg RM et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91.
  • Tournigand C et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400.
  • Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
  • André T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343-51.
  • de Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000:2938−47.